Why CanniMed Therapeutics Inc. Soared 17.18% on Thursday

CanniMed Therapeutics Inc. (TSX:CMED) soared 17.18% on Thursday after announcing that it will discuss a possible deal with Aurora Cannabis Inc. (TSX:ACB). What should you do now?

| More on:

What?

Canadian medical cannabis producer CanniMed Therapeutics Inc. (TSX:CMED) watched its stock roar 17.18% higher in Thursday’s trading session following its announcement that it has postponed its special shareholders’ meeting to vote on its proposed takeover of Newstrike Resources Ltd. (TSXV:HIP) in order to discuss a possible transaction with Aurora Cannabis Inc. (TSX:ACB).

So what?

Aurora had originally tried to acquire CanniMed in November, but CanniMed was not a fan of the deal and has done everything in its power to prevent it, including launching its takeover of Newstrike Resources and filing a $725 million lawsuit against Aurora, but it seems like the two sides are finally on speaking terms and will meet to discuss a potential deal.

Aurora has been accumulating shares of CanniMed since announcing its intention to take the company over on November 24, with its most recent press release showing an aggregate number of shares purchased at 700,600, which have a market value of approximately $22.84 million at the close of trading on Thursday, but it has agreed to not acquire any additional shares during the standstill period that will last until January 21 at 11:59 P.M. (EST).

Now what?

Cannabis is right up there with cryptocurrency and blockchain technology as one of the most-talked-about topics in the investment world today, especially in Canada, and it has been one of the most active in terms of deal making as well. I think a deal between CanniMed and Aurora would make the combined company an absolute powerhouse in the industry with far greater long-term growth potential, and it would give it elite status alongside Canopy Growth Corp. and Aphria Inc. in my mind, so I am definitely rooting for the deal to get done. 

With all of this being said, I would avoid making new investments in CanniMed or Aurora until we know more about the possible deal on January 21, so stay tuned!

Fool contributor Joseph Solitro has no position in any stocks mentioned.

More on Investing

chart reflected in eyeglass lenses
Dividend Stocks

2 Canadian Dividend Stocks That Look Reasonably Priced Right Now

These top TSX dividend stocks are off their 2026 highs.

Read more »

boy in bowtie and glasses gives positive thumbs up
Dividend Stocks

A Year Later: 2 Stocks I’d Buy Again Without Hesitating

Brookfield and WSP have already had a strong year, but their earnings momentum and long runways still make them look…

Read more »

Income and growth financial chart
Dividend Stocks

1 Canadian Stock That Could Be Set Up for a Big Comeback in 2026

CN remains well below the 2024 highs. Is this the right time to buy?

Read more »

Piggy bank on a flying rocket
Tech Stocks

The Lesser-Known Habits That Most TFSA Millionaires Share

Most TFSA millionaires share a few overlooked habits. Here is what they do differently, and how a stock like Kraken…

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Tuesday, April 21

Despite inching higher to remain near record highs in the last session, mixed commodity trends and global risks could keep…

Read more »

man in bowtie poses with abacus
Energy Stocks

The $109,000 TFSA Milestone: How Do You Stack Up?

Hitting the $109,000 TFSA milestone isn’t about perfection, it’s about building consistent habits that make tax-free income possible.

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

Retiring? $1 Million Isn’t Enough Anymore

$1,000,000 invested in iShares S&P/TSX 60 Index Fund (TSX:XIU) doesn't provide enough income to retire on.

Read more »

chart reflected in eyeglass lenses
Stocks for Beginners

3 TSX Stocks to Buy if You Think the TSX Stays Resilient

These three TSX stocks mix steady demand and growth potential across insurance, healthcare, and energy services.

Read more »